Intelgenx Technologies Aktie - IGX

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

0,24

Gebot

0,05

Fragen

0,15

Volumen

0,00 Tagesbereich 0,00

0,185 52-Wochen-Bereich 0,26

Handelsende

0,24

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process

MONTREAL, July 19, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”) (OTC:...

IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

MONTREAL, July 03, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of...

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of...

IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process

MONTREAL, May 28, 2024 (GLOBE NEWSWIRE) -- As previously announced on May 17, 2024, IntelGenx Technologies...

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

MONTREAL, May 17, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”...

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

MONTREAL, May 17, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”...

IntelGenx Announces Voting Results on Election of Directors

SAINT LAURENT, Quebec, May 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT...

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the...

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the...

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0.24	0.24	0.24	0	0	CS
4	0	0	0.24	0.24	0.24	0	0	CS
12	0	0	0.24	0.24	0.24	0	0	CS
26	0	0	0.24	0.24	0.24	0	0	CS
52	-0.01	-4	0.25	0.26	0.185	2496	0.22391088	CS
156	-0.11	-31.4285714286	0.35	0.485	0.135	17149	0.23206831	CS
260	-0.34	-58.6206896552	0.58	0.79	0.135	21042	0.346677	CS

IGX - Frequently Asked Questions (FAQ)

What is the current Intelgenx Technologies share price?

The current share price of Intelgenx Technologies is $ 0,24

What is the 1 year trading range for Intelgenx Technologies share price?

Intelgenx Technologies has traded in the range of $ 0,185 to $ 0,26 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
APSAptose Biosciences Inc	$ 4,80 (35,21%)	14,75k
SMCSulliden Mining Capital Inc	$ 0,025 (25,00%)	238,5k
GRCGold Springs Resource Corp	$ 0,07 (16,67%)	3,5k
KRNKarnalyte Resources Inc	$ 0,185 (15,63%)	6k
AMMAlmaden Minerals Ltd New	$ 0,12 (14,29%)	176,5k
BKIBlack Iron Inc	$ 0,09 (-25,00%)	1,73M
DII.BDorel Industries Inc	$ 1,33 (-23,12%)	78,36k
OPTOptiva Inc	$ 1,50 (-21,05%)	2,7k
BRYBri Chem Corp	$ 0,24 (-20,00%)	3,1k
DSV.RDiscovery Silver Corp	$ 1,71 (-17,79%)	309
CNQCanadian Natural Resources Ltd	$ 39,25 (-6,66%)	22,74M
BTEBaytex Energy Corp	$ 2,32 (-17,14%)	14,14M
SUSuncor Energy Inc	$ 47,24 (-8,86%)	12,13M
WCPWhitecap Resources Inc	$ 7,76 (-9,87%)	11,86M
TRPTC Energy Corporation	$ 65,41 (-4,73%)	10,68M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Intelgenx Technologies Corp (IGX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

IGX Neueste Nachrichten

IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process

IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Announces Voting Results on Election of Directors

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process

IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Announces Voting Results on Election of Directors

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

IGX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Intelgenx Technologies Corp (IGX) Börsenkurse

Intelgenx Technologies Corp (IGX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

IGX Neueste Nachrichten

IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process

IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Announces Voting Results on Election of Directors

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process

IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Announces Voting Results on Election of Directors

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

IGX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen